This 168-page report, “Global Pharmaceutical Contract Research Organization (CRO) Market 2020-2030 by Service, Therapeutic Application, End User, and Region: Trend Forecast and Growth Opportunity,” is highlighted by 85 tables and 77 figures and is based on extensive research of the entire global pharmaceutical CRO market and all of its sub-segments. Premium primary and secondary information sources are used to create in-depth research and assessment, with input coming from business specialists working across the value chain.
By 2030, the global pharmaceutical CRO market will be worth $104.4 billion, growing by 8.1% year between 2020–2030 due to factors such as rising illness incidence, rising healthcare costs, and growing reliance on CROs because of their increased productivity and efficiency.
The research uses 2019 as the foundation year for its estimate, which ranges from 2020 to 2030 and is based on studies from 2015 to 2019. (Please note that the report will be updated before to delivery to ensure that the forecast includes at least 5 years past the base year and the most recent historical year serves as the base year.)
Request Research Sample with Latest Industry Insights (168+ Pages Report): https://altusmarketresearch.com/reports/sample/3452
Pharmaceutical CRO Market: The following aspects are identified and examined in-depth qualitative analyses:
• Market Organization
• Growth Agents
• Challenges and Restrictions
• Market Opportunities & Emerging Product Trends
• Fiver Forces Porter
By taking COVID-19 into consideration, the trend and outlook for the global market are predicted with an upbeat, fair-minded, and conservative viewpoint. The global pharmaceutical CRO market is quantified from the viewpoints of service, therapeutic application, end user, and region using the balanced (most likely) projection.
The global Pharmaceutical CRO Market is divided into the following sub-markets based on service, with annual revenue for 2019–2030 provided in each sector.
• CRO for Pre-clinical Development
• CRO for Phase I Trials
• CRO for Phase II Trials
• CRO for Phase III Trials
• CRO for Phase IV Trials
• Laboratory Services
• Consulting Services
• Data Management Services
Based on Therapeutic Application, the global Pharmaceutical CRO Market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Infectious Diseases
• Oncology
• Metabolic Disorders
• Cardiovascular Disorders
• Central Nervous System
• Respiratory Disorders
• Gastrointestinal Disorders
• Other Therapeutic Applications
Based on End User, the global Pharmaceutical CRO Market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Pharmaceutical & Biopharmaceutical Companies
• Medical Device Companies
• Academic Institutes
Along with the listed national/local markets, the following geographic areas are thoroughly investigated:
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
In Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Turkey, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• America, North (U.S., Canada, and Mexico)
Latin America (Brazil, Chile, Argentina, Rest of South America)
• MEA (Saudi Arabia, UAE, South Africa) (Saudi Arabia, UAE, South Africa)
There are thorough analyses and data for annual revenue for each of the aforementioned regions and nations for the years 2019 through 2030. All regional markets are broken down by country, and major national markets are divided by service, therapeutic application, and end user for the forecasted years.
The study also analyses the present competition landscape, the anticipated trend, and it provides profiles of key vendors, including both established market leaders and significant up-and-coming companies.
Through AMR’s Risk Assessment System, possible risks related to investments in the worldwide pharmaceutical CRO industry are evaluated quantitatively and qualitatively. Critical Success Factors (CSFs) are developed based on the risk analysis and evaluation as a guide to assist investors and stockholders in identifying emerging possibilities, managing and minimising risks, developing suitable business models, and making informed strategies and decisions.
Key Players (this list may not be exhaustive; additional businesses can be included upon request):
Charles River Laboratories
CMIC Co. Ltd
Covance Inc.
Hangzhou Tigermed Consulting Co Ltd
ICON Plc
IQVIA Holdings Inc.
LSK Global Pharma Service Co Ltd
Novotech Pty Ltd
PAREXEL International Corporation
Pharmaceutical Product Development LLC (PPD)
PRA Health Sciences Inc.
Quanticate Ltd
Samsung Bioepis Co. Ltd
SGS SA (SGS Life Sciences)
Syneos Health Inc.
WuXi AppTec Inc.
